<DOC>
	<DOCNO>NCT00487825</DOCNO>
	<brief_summary>This study intend evaluate safety efficacy intravenous ( IV ) ACZ885 oral methotrexate ( MTX ) therapy patient early rheumatoid arthritis ( RA )</brief_summary>
	<brief_title>Safety Efficacy Intravenous ACZ885 Oral Methotrexate Therapy Patients With Early Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female patient 18 75 year age ( inclusive ) Recent definite diagnosis rheumatoid arthritis ( RA ) ( &lt; 3 year since diagnosis ) , classified American Rheumatism Association 1987 revise criterion . Candidate methotrexate ( MTX ) biologic due erosive arthritis , contraindication therapy , include : Negative tuberculin skin test reaction Normal chest Xray ( within last year ) prior possibility receive MTX ( r/o lung fibrosis ) . Active disease : least 6 swollen 6 painful tender joint 28 joint count , Vital sign within follow range : 1859 year age : oral temperature 35.037.5 °C systolic blood pressure , 90140 mm Hg diastolic blood pressure , 5090 mm Hg pulse rate , 40 90 beat per minute 6075 year age : oral temperature 35.037.5 °C systolic blood pressure , 100160 mm Hg diastolic blood pressure , 50100 mm Hg pulse rate , 50 100 beat per minute Women childbearing potential willing practice doublebarrier contraception study least 3 month follow last study drug administration . Postmenopausal woman must regular menstrual bleeding least 1 year prior inclusion . Surgically sterilized woman least 6 month prior screen . Male patient must use doublebarrier local contraception refrain father child 3 month follow last study drug administration . Weight : least 45 kg ; body mass index ( BMI ) within range 18 34 . Oral corticosteroid permit long patient stable dose ( 10 mg ) least 4 week study start . Unable Magnetic Resonance Imaging ( MRI ) wrist . Patients magnetizable metal parts/devices body could interfere MRI Patients unstable active medical condition could impair evaluation study result . Previous treatment biological therapy MTX . Limited kidney function ( creatinine clearance 60 ml/min ) Previous treatment diseasemodifying antirheumatic drug sulfasalazine , hydroxychloroquine within 4 week screen . Corticosteroids injection joint within 4 week prior screen . Participation clinical investigation within 4 week prior study start longer required local regulation , limitation participation base local regulation . Blood donation loss &gt; 400 mL within 8 week study start , longer required local regulation . Significant illness within 2 week study start . Past personal family medical history clinically significant ECG abnormality cardiac issue . History : fainting , orthostatic hypotension , sinus arrhythmia asthma chronic obstructive pulmonary disease , clinically significant drug allergy urticaria , eczematous dermatitis , and/or know hypersensitivity study drug drug similar study drug . disease blood building system , serious active infection , gastric ulcer . surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize patient case participation study . immunodeficiency disease , include positive Human Immunodeficiency Virus ( HIV ) ( ELISA Western blot ) test result . positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . drug alcohol abuse within 12 month prior dose evidence abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>ACR20 , ACR50 , ACZ885 ( anti-interleukin-1beta monoclonal antibody ) , rheumatoid arthritis , methotrexate</keyword>
</DOC>